|Application ||WB, IHC-P, E|
|Calculated MW||30392 Da|
|Dilution||ELISA (1:32000), IHC-P (5 µg/ml), WB (0.03 - 0.1 µg/ml)|
|Other Names||TNFRSF14, CD270, CD270 antigen, CD40-like protein, Herpesvirus entry mediator, Herpesvirus entry mediator A, HVEM, LIGHTR, Herpes virus entry mediator A, TR2, ATAR, HVEA|
|Reconstitution & Storage||Immunoaffinity purified|
|Precautions||Anti-TNFRSF14 / CD270 / HVEM Antibody (aa240-251) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Receptor for BTLA. Receptor for TNFSF14/LIGHT and homotrimeric TNFSF1/lymphotoxin-alpha. Involved in lymphocyte activation. Plays an important role in HSV pathogenesis because it enhanced the entry of several wild-type HSV strains of both serotypes into CHO cells, and mediated HSV entry into activated human T-cells.|
|Cellular Location||Membrane; Single-pass type I membrane protein|
|Tissue Location||Widely expressed, with the highest expression in lung, spleen and thymus|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.